Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • rrtzrealmd rrtzrealmd Mar 10, 2014 12:01 PM Flag

    HAW!!! Talk about biotech "doubletalk"!

    ...today's PR announcing, "The data reported today showed that OMS721 significantly inhibited complement deposition in the model...blah, blah, blah..." is one of the better examples I've seen....

    ...at first, I thought it meant they had actual samples from aHUS patients that they tested the drug on -- but I then I saw "model" after I read it again more CAREFULLY and recognized what it REALLY said...

    ...first, note that all it really announces is that this Italian dude has an "experimental MODEL...based on the finding that serum samples from aHUS patients cause complement deposition and thrombus formation when incubated with human microvascular endothelial cells."...

    ...then gOMER reports that "...OMS721 significantly inhibited complement deposition in the MODEL using serum samples from aHUS patients..."...

    ...so here is this MODEL about which we have NO idea regarding its validity in which OMS721 inhibits complement...

    ...well, geeeeee!...even disregarding our ignorance of the validity of the model, isn't that just PRECLINICAL data?...I mean, isn't gOMER supposedly PAST that?...after all, it hardly seems relevant to be publishing PRECLINICAL data when you're ALREADY PAST the phase 1 stage!...ESPECIALLY considering by NOW you should have ALREADY demonstrated the stuff's ability to inhibit the MASP pathway!...

    ...I think we should all stand for a minute and give gOMER a big round of "slow clapping" for gOMER!...come on!...whad'ya say?!....HAW!!!....

 
OMER
11.16-0.06(-0.53%)Sep 30 4:00 PMEDT